Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F

Biochemistry

Volumn 48, Issue 24, 2009, Pages 5631-5641

  Fu, Zhuji ^a   Chen, Chen ^a   Barbieri, Joseph T ^a   Kim, Jung Ja P ^a   Baldwin, Michael R ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING POCKETS; BOTULINUM NEUROTOXINS; DEGLYCOSYLATION; FUNCTION PROPERTIES; GALACTOSIDASE; GLYCANS; GLYCOSYLATED; HIGH AFFINITY; HIPPOCAMPAL NEURONS; KERATAN SULFATE; MOTOR NEURONS; NEUROMUSCULAR JUNCTIONS; NEUTRAL SACCHARIDES; NO BINDING; PNGASE F; PROTEIN COMPLEXES; RECEPTOR INTERACTION; RECEPTOR-BINDING DOMAINS; SEROTYPE; SEROTYPES; SIALIC ACIDS; SOLID-PHASE; STRUCTURAL BASIS; SYNAPTIC VESICLE; SYNAPTOTAGMIN;

AFFINITY CHROMATOGRAPHY; CARBOHYDRATES; CARBOXYLIC ACIDS; CHROMATOGRAPHIC ANALYSIS; GLYCOPROTEINS; PROTEINS;

NEURONS;

ALPHA LEVO FUCOSIDASE; BOTULINUM TOXIN A; BOTULINUM TOXIN F; GALACTOSE; GALACTOSIDASE; GANGLIOSIDE; GANGLIOSIDE GD 1A; GLYCAN; GLYCOPROTEIN; GLYCOSYLATED PROTEIN; KERATAN SULFATE; N ACETYLLACTOSAMINE SYNTHASE; OLIGOSACCHARIDE; POLYPEPTIDE; SIALIC ACID; SYNAPTOTAGMIN I;

AFFINITY CHROMATOGRAPHY; ANALYTIC METHOD; ARTICLE; CRYSTAL STRUCTURE; DEGLYCOSYLATION; MUTATION; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; SYNAPSE VESICLE;

ANIMALS; BINDING SITES; BOTULINUM TOXIN TYPE A; BOTULINUM TOXINS; GANGLIOSIDES; GLYCOSYLATION; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; NEURONS; PROTEIN CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC VESICLES;

RATTUS;

EID: 67649210455     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi9002138     Document Type: Article

References (58)

1. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M. T., O'Toole, T., Parker, G., Perl, T. M., Russell, P. K., Swerdlow, D. L., and Tonat, K. (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285, 1059-1070. (Pubitemid 32176420)
2. Hatheway, C. L. (1995) Botulism: the present status of the disease. Curr. Top. Microbiol. Immunol. 195, 55-75.
3. Johnson, E. A. (1999) Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 53, 551-575.
4. Johnson, E. A., and Bradshaw, M. (2001) Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon 39, 1703-1722. (Pubitemid 32787002)
5. Moller, V., and Scheibel, I. (1960) Preliminary report on the isolation of an apparently new type of CI. botulinum. Acta Pathol. Microbiol. Scand. 48, 80.
6. Rymkiewicz, D. (1968) Studies on Clostridium botulinum type F. I. Properties of selected cultures of the Langeland strain. Med. Dosw Mikrobiol. 20, 169-174.
7. Barash, J. R., Tang, T. W., and Arnon, S. S. (2005) First case of infant botulism caused by Clostridium baratii type F in California. J. Clin. Microbiol. 43, 4280-4282.
8. East, A. K., Richardson, P. T., Allaway, D., Collins, M. D., Roberts, T. A., and Thompson, D. E. (1992) Sequence of the gene encoding type F neurotoxin of Clostridium botulinum. FEMS Microbiol. Lett. 75, 225-230.
9. Eklund, M. W., Poysky, F. T., and Wieler, D. I. (1967) Characteristics of Clostridium botulinum type F isolated from the Pacific coast of the United States. Appl. Microbiol. 15, 1316-1323.
10. Harvey, S. M., Sturgeon, J., and Dassey, D. E. (2002) Botulism due to Clostridium baratii type F toxin. J. Clin. Microbiol. 40, 2260-2262.
11. Smith, T. J., Lou, J., Geren, I. N., Forsyth, C. M., Tsai, R., Laporte, S. L., Tepp, W. H., Bradshaw, M., Johnson, E. A., Smith, L. A., and Marks, J. D. (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73, 5450-5457.
12. Montecucco, C., Rossetto, O., and Schiavo, G. (2004) Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 12, 442-446. (Pubitemid 39286121)
13. Dong, M., Richards, D. A., Goodnough, M. C., Tepp, W. H., Johnson, E. A., and Chapman, E. R. (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162, 1293-1303. (Pubitemid 37210885)
14. Chai, Q., Arndt, J. W., Dong, M., Tepp, W. H., Johnson, E. A., Chapman, E. R., and Stevens, R. C. (2006) Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-1100. (Pubitemid 46018532)
15. Dong, M., Tepp, W. H., Liu, H., Johnson, E. A., and Chapman, E. R. (2007) Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J. Cell Biol. 179, 1511-1522.
16. Jin, R., Rummel, A., Binz, T., and Brunger, A. T. (2006) Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095. (Pubitemid 46018531)
17. Rummel, A., Karnath, T., Henke, T., Bigalke, H., and Binz, T. (2004) Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 279, 30865-30870.
18. Sonnino, S., Mauri, L., Chigorno, V., and Prinetti, A. (2007) Gangliosides as components of lipid membrane domains. Glycobiology 17, 1R-13R. (Pubitemid 44932810)
19. Abad-Rodriguez, J., and Robotti, A. (2007) Regulation of axonal development by plasma membrane gangliosides. J. Neurochem. 103 (Suppl 1), 47-55.
20. Bullens, R. W., O'Hanlon, G. M., Wagner, E., Molenaar, P. C., Furukawa, K., Plomp, J. J., and Willison, H. J. (2003) Roles of complex gangliosides at the neuromuscular junction. Ann. N. Y. Acad. Sci. 998, 401-403.
21. Yowler, B. C., Kensinger, R. D., and Schengrund, C. L. (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J. Biol. Chem. 277, 32815-32819.
22. Kitamura, M., Takamiya, K., Aizawa, S., and Furukawa, K. (1999) Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. Biochim. Biophys. Acta 1441, 1-3.
23. Nishiki, T., Tokuyama, Y., Kamata, Y., Nemoto, Y., Yoshida, A., Sato, K., Sekiguchi, M., Takahashi, M., and Kozaki, S. (1996) The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 378, 253-257. (Pubitemid 126334514)
24. Ochanda, J. O., Syuto, B., Ohishi, I., Naiki, M., and Kubo, S. (1986) Binding of Clostridium botulinum neurotoxin to gangliosides. J Biochem (Tokyo) 100, 27-33. (Pubitemid 16093950)
25. Kitamura, M., Iwamori, M., and Nagai, Y. (1980) Interaction between Clostridium botulinum neurotoxin and gangliosides. Biochim. Biophys. Acta 628, 328-335.
26. Rummel, A., Mahrhold, S., Bigalke, H., and Binz, T. (2004) The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51, 631-643.
27. Rummel, A., Bade, S., Alves, J., Bigalke, H., and Binz, T. (2003) Two carbohydrate binding sites in the H(CC)-domain of tetanus neurotoxin are required for toxicity. J. Mol. Biol. 326, 835-847.
28. Dong, M., Liu, H., Tepp, W. H., Johnson, E. A., Janz, R., and Chapman, E. R. (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 19, 5226-5237.
29. Nishiki, T., Kamata, Y., Nemoto, Y., Omori, A., Ito, T., Takahashi, M., and Kozaki, S. (1994) Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 269, 10498-10503.
30. Nishiki, T., Ogasawara, J., Kamata, Y., and Kozaki, S. (1993) Solubilization and characterization of the acceptor for Clostridium botulinum type B neurotoxin from rat brain synaptic membranes. Biochim. Biophys. Acta 1158, 333-338.
31. Nishiki, T., Tokuyama, Y., Kamata, Y., Nemoto, Y., Yoshida, A., Sekiguchi, M., Takahashi, M., and Kozaki, S. (1996) Binding of botulinum type B neurotoxin to Chinese hamster ovary cells transfected with rat synaptotagmin II cDNA. Neurosci. Lett. 208, 105-108.
32. Dong, M., Yeh, F., Tepp, W. H., Dean, C., Johnson, E. A., Janz, R., and Chapman, E. R. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596.
33. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B., and Binz, T. (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011-2014.
34. Baldwin, M. R., Tepp, W. H., Przedpelski, A., Pier, C. L., Bradshaw, M., Johnson, E. A., and Barbieri, J. T. (2008) Subunit vaccine against the seven serotypes of botulism. Infect. Immun. 76, 1314-1318.
35. Huttner, W. B., Schiebler, W., Greengard, P., and De Camilli, P. (1983) Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J. Cell Biol. 96, 1374-1388.
36. Baldwin, M. R., and Barbieri, J. T. (2007) Association of botulinum neurotoxin serotypes A and B with synaptic vesicle protein complexes. Biochemistry 46, 3200-3210. (Pubitemid 46449141)
37. Bochner, B. S., Alvarez, R. A., Mehta, P., Bovin, N. V., Blixt, O., White, J. R., and Schnaar, R. L. (2005) Glycan array screening reveals a candidate ligand for Siglec-8. J. Biol. Chem. 280, 4307-4312.
38. Otwinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326. (Pubitemid 27085611)
39. Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R., and Stevens, R. C. (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5, 898-902.
40. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D 54, 905-921.
41. Roussel, A., and Inisan, A. G. (1999) Turbo-Frodo, version OpenGL:1; CNRS/Universitite Marseille: Marseille, France.
42. Schiavo, G., Benfenati, F., Poulain, B., Rossetto, O., Polverino de Laureto, P., DasGupta, B. R., and Montecucco, C. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832-835.
43. Ogawa-Goto, K., and Abe, T. (1998) Gangliosides and glycosphingolipids of peripheral nervous system myelins: A minireview. Neurochem. Res. 23, 305-310.
44. Jayaraman, S., Eswaramoorthy, S., Kumaran, D., and Swaminathan, S. (2005) Common binding site for disialyllactose and tri-peptide in C-fragment of tetanus neurotoxin. Proteins 61, 288-295. (Pubitemid 41429136)
45. Umland, T. C., Wingert, L. M., Swaminathan, S., Furey, W. F., Schmidt, J. J., and Sax, M. (1997) Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat. Struct. Biol. 4, 788-792.
46. Lalli, G., Herreros, J., Osborne, S. L., Montecucco, C., Rossetto, O., and Schiavo, G. (1999) Functional characterisation of tetanus and botulinum neurotoxins binding domains. J. Cell Sci. 112 (Pt 16), 2715-2724. (Pubitemid 29429794)
47. Kumaran, D., Eswaramoorthy, S., Furey, W., Navaza, J., Sax, M., and Swaminathan, S. (2009) Domain organization in Clostridium botulinum neurotoxin type E is unique: Its implication in faster translocation. J. Mol. Biol. 386, 233-245.
48. Yowler, B. C., and Schengrund, C. L. (2004) Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. Biochemistry 43, 9725-9731. (Pubitemid 38993822)
49. Kozaki, S., Kamata, Y., Watarai, S., Nishiki, T., and Mochida, S. (1998) Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb. Pathog. 25, 91-99.
50. Kitamura, M., Igimi, S., Furukawa, K., and Furukawa, K. (2005) Different response of the knockout mice lacking b-series gangliosides against botulinumand tetanus toxins. Biochim. Biophys. Acta 1741, 1-3.
51. Fotinou, C., Emsley, P., Black, I., Ando, H., Ishida, H., Kiso, M., Sinha, K. A., Fairweather, N. F., and Isaacs, N. W. (2001) The crystal structure of tetanus toxin Hc fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J. Biol. Chem. 276, 32274-32281.
52. Stenmark, P., Dupuy, J., Imamura, A., Kiso, M., and Stevens, R. C. (2008) Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 4, e1000129.
53. Schivell, A. E., Batchelor, R. H., and Bajjalieh, S. M. (1996) Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J. Biol. Chem. 271, 27770-27775.
54. Schivell, A. E., Mochida, S., Kensel-Hammes, P., Custer, K. L., and Bajjalieh, S. M. (2005) SV2A and SV2C contain a unique synaptotagmin- binding site. Mol. Cell Neurosci. 29, 56-64.
55. Lazzell, D. R., Belizaire, R., Thakur, P., Sherry, D. M., and Janz, R. (2004) SV2B regulates synaptotagmin 1 by direct interaction. J. Biol. Chem. 279, 52124-52131.
56. Scranton, T. W., Iwata, M., and Carlson, S. S. (1993) The SV2 protein of synaptic vesicles is a keratan sulfate proteoglycan. J. Neurochem. 61, 29-44. (Pubitemid 23175881)
57. Sinouris, E. A., Skandalis, S. S., Kilia, V., Theocharis, A. D., Theocharis, D. A., Ravazoula, P., Vynios, D. H., and Papageorgakopoulou, N. (2009) Keratan sulfate-containing proteoglycans in sheep brain with particular reference to phosphacan and synaptic vesicle proteoglycan isoforms. Biomed. Chromatogr. 23, 455-463.
58. Chen, C., Baldwin, M. R., and Barbieri, J. T. (2008) Molecular basis for tetanus toxin coreceptor interactions. Biochemistry 47, 7179-7186. (Pubitemid 351956366)